You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.


Go back


Duac Once Daily Gel is a fixed dose combination therapy indicated for the topical treatment of mild-to-moderate acne vulgaris, particularly inflammatory lesions, in adults and adolescents aged 12 years and above.

Learn More

Clinical Presentation

Information on the forms of acne including visual depictions of acne lesions and pathogenesis.

Clinical Indications

Clinical Evidence

View clinical data comparing combination therapy with clindamycin/benzol peroxide to alternative combination and monotherapies.

Clinical Evidence

Prevalence of Acne

Click here for information on acne prevalence and patient demographics.

Prevalence of Acne

Acne Patient Burden

Review data on the psychosocial and emotional burden of ance.

Patient Burden

How to prescribe

Duac dosage and administration.

Prescribe Duac

Download the acne grading card that demonstrates the different levels of acne

Download now

Adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971, Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Duac is a registered trademark of Stiefel Laboratories Inc., a GSK company.